 OutSourcing-Pharma.com | Sanofi signs $900m allergy collaboration with Selecta PMLiVE In addition to targeting allergens, it has also been used to develop investigational therapies in autoimmune diseases, protein replacement therapy and transplant rejection. The deal comes shortly after the appointment of Dr Gary Nabel, who has a ... Selecta Biosciences and Sanofi Sign Global Collaboration to Develop Antigen ... |
